4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Rating of “Moderate Buy” from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given an average rating of “Moderate Buy” by the ten analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $42.13.

A number of analysts have weighed in on FDMT shares. Morgan Stanley assumed coverage on 4D Molecular Therapeutics in a research report on Thursday, November 21st. They set an “underweight” rating and a $8.00 price objective for the company. Chardan Capital reiterated a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Leerink Partners reaffirmed an “outperform” rating and issued a $36.00 target price (down previously from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Finally, Royal Bank of Canada dropped their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $6.50 on Friday. 4D Molecular Therapeutics has a fifty-two week low of $6.41 and a fifty-two week high of $36.25. The firm has a 50-day simple moving average of $8.09 and a 200-day simple moving average of $14.61. The company has a market capitalization of $300.48 million, a price-to-earnings ratio of -2.28 and a beta of 2.74.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC increased its holdings in 4D Molecular Therapeutics by 141.0% in the third quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after buying an additional 67,202 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its stake in shares of 4D Molecular Therapeutics by 81.3% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company’s stock worth $265,000 after acquiring an additional 11,002 shares in the last quarter. State Street Corp grew its holdings in shares of 4D Molecular Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after acquiring an additional 37,232 shares during the period. Redmile Group LLC increased its stake in 4D Molecular Therapeutics by 17.6% in the 3rd quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock valued at $13,643,000 after purchasing an additional 188,655 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in 4D Molecular Therapeutics during the third quarter worth $166,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.